JPRN-UMIN000018871CompletedPhase 4
Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS study) - Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS study)
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Osaka University
- Enrollment
- 31
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 65years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Type 1 diabetes mellitus 2. Moderate or severe renal dysfunction (eGFR<45 ml/min/1.73m2 or hemodialysis) 3. Severe hepatic insufficiency (AST and/or ALT >3x upper limit of normal) 4. Adrenal insufficiency or pituitary gland dysfunction 5. Malnourishment, starvation, irregular dietary intake, poor dietary intake, debilitating condition or a severe muscle movement 6. Volume depleted patients; concomitant medication such as loop diuretics. 7. Excessive alcohol intake (>60g daily) 8. SGLT2 inhibitors such as dapagliflozin are already administered 9. Contraindication with dapagliflozin 10. Start a new medication of statins, fibratesm ezetimibe or probucol within a month 11. Females who are likely to be pregnant, during pregnancy or lactating 12. Participants in other clinical trials 13. Inability to communicate and comply with all study requirements.
Investigators
Similar Trials
Unknown
Phase 4
Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)Diabetes Mellitus, Type 2NCT02577159Osaka University50
Completed
Not Applicable
Effect of Dapagliflozin (Forxiga) on hepatic lipid content and microbiota in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitusType 2 diabetes mellitusJPRN-UMIN000030498Tokai University17
Completed
Not Applicable
Dapagliflozin on cholesterol metabolism in DM2: dissecting its effect on dyslipidemia by using stable isotope based cholesterol and glucose fluxesdiabetes mellitusNL-OMON43515Academisch Medisch Centrum12
Completed
Not Applicable
Dapagliflozin on cholesterol metabolism in DM2: dissecting its effect on dyslipidemia by using stable isotope based cholesterol and glucose fluxesdiabetes type 2dyslipidemiaNL-OMON28993AMC12
Completed
Phase 4
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic PatientsType 2 DiabetesNCT02327039University of Padova33